Antiviral HBV Library
ChemDiv’s HBV focusing subside of antiviral library contains 11,000 compounds.
Infection by the Hepatitis B virus (HBV) induces numerous changes in hepatocytes, attributable both to the direct action of a virus-encoded protein, HBx, and to indirect alterations deriving from a significant increase in intracellular reactive oxygen species (ROS) following infection. HBx disrupts various cellular pathways, partly through its binding to genomic DNA, which alters the expression patterns of miRNAs. Additionally, it interferes with histone methyltransferases, associates with the SIRT1 protein to activate transcription, and collaborates with histone methylases and demethylases to modify cellular expression profiles. HBx is substantially implicated in the roughly 10,000-fold escalation of intracellular ROS observed in chronic HBV infection. This increase in ROS is partly induced by the localization of HBx to the mitochondria, where it diminishes mitochondrial membrane potential.
The HBV subset of the small molecule library, focusing on antiviral compounds, is specifically tailored for targeting HBV with a distinct emphasis on non-nucleoside compounds. This collection comprises a diverse array of small molecules designed to interfere with various non-nucleoside targets of HBV, such as the HBx protein and other crucial viral enzymes, without mimicking the nucleoside structures of viral DNA. By exploring innovative chemical spaces and employing techniques like isosteric transformations and scaffold hopping, the library aims to uncover novel inhibitors that can disrupt HBV replication and protein interactions, offering potential new avenues for effective HBV treatment beyond the conventional nucleoside analogs.
This small molecule library, specifically tailored for antiviral drug discovery, presents significant benefits for pharmaceutical and biomedical research sectors. Its unique focus on non-nucleoside compounds for HBV provides an avenue for the development of innovative treatments that overcome the limitations of current therapies, including reduced risk of viral resistance and fewer side effects. The library's diverse range of compounds, designed using advanced techniques like isosteric transformations and scaffold hopping, not only enhances the probability of discovering highly effective and selective antiviral agents but also accelerates the drug development process. This collection is especially valuable for companies seeking to expand their antiviral portfolio with novel compounds, offering a competitive edge in the rapidly evolving field of antiviral therapeutics. Additionally, the library serves as a robust resource for academic and industry researchers exploring new mechanisms of HBV inhibition, thus fostering advancements in both scientific understanding and therapeutic approaches.